Shire to present Vyvanse, Intuniv studies at psychiatrist meetings
PHILADELPHIA British drug maker Shire will present data on two attention deficit hyperactivity disorder treatments in New Orleans starting this week, Shire said.
The company said it would present data on Vyvanse (lisdexamfetamine dimesylate) capsules and Intuniv (guanfacine) extended-release tablets at two psychiatrist meetings between Thursday and Wednesday.
“We believe that the Vyvanse and Intuniv study findings will be an important contribution to the current collection of ADHD research,” Shire Pharmaceuticals SVP research and development Jeffrey Jonas said. “These studies reflect Shire’s commitment to advancing ADHD treatment research.”
MinuteClinic opens two Mass. locations
WOONSOCKET, R.I. MinuteClinic, which is owned by CVS Caremark, has expanded its Massachusetts-based clinics to 20 with Wednesday’s opening of two new locations in Hanover and Quincy.
"Since opening our first store-based clinic in Massachusetts in 2008, we have helped to expand access to high-quality, convenient and affordable care to thousands of residents who have visited us at convenient CVS/pharmacy locations near where they live and work," stated Andrew Sussman, president of MinuteClinic and SVP/associate chief medical officer of CVS Caremark. "We are committed to working with the medical community in Massachusetts to build on the state’s precedent-setting efforts to broaden access to quality health services."
According to MinuteClinic, it has had more than 50,000 patient visits in Massachusetts (not including flu shot visits) in less than two years. About 70% of the patients seen at MinuteClinic locations in Massachusetts do not identify a primary care provider. MinuteClinic offers those patients without a primary care provider information on nearby practices accepting new patients.
Hospira extends acquisition offer to Javelin
LAKE FOREST, Ill. Hospira has extended its $145 million offer to buy Javelin Pharmaceuticals, the generic drug maker said Wednesday.
The offer, originally made in April, was set to expire at the end of Tuesday, but will now expire at the end of June 2.
Hospira said Javelin had not satisfied all the conditions for acquisition, which Javelin said was due to a supply-chain problem with the painkiller Dyloject in the United Kingdom, though Javelin expressed disagreement with Hospira’s position.